BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...approach that does not depend on E3 ubiquitin ligases.The Glasglow-based company spun out of the University of Dundee...
...million) Investors: Advent Life Sciences, Scottish Investment Bank and BioMotivCEO: Nicola ThompsonPatents: None issued Danielle Golovin Amphista Therapeutics Ltd. University of Dundee Advent...
BioCentury | Apr 9, 2020
Finance

April 8 Quick Takes: Amphista’s series A; Invitae, Fudan-Zhangjiang and MedGenome

...investor BioMotiv. The Glasgow-based company, which spun out of Professor Alessio Ciulli’s labs at the University of Dundee...
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...was developed using Exscientia’s Centaur Chemist AI platform, which combines AI and human expertise. The University of Dundee...
...Discoidin domain receptor tyrosine kinase 1 Karen Tkach Tuzman, Associate Editor Exscientia Ltd. Dainippon Sumitomo Pharma Co. Ltd. AI DSP-1181 University of Dundee...
BioCentury | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

...Tokyo:4523) is the latest company to enter the targeted degradation field through a collaboration with University of Dundee...
...plc Jazz Pharmaceuticals plc Mirati Therapeutics Inc. Myovant Sciences GmbH Neurocrine Biosciences Inc. Novartis Novartis AG Novo Nordisk A/S Redx Pharma plc Revolution Medicines Inc. Roche Sanofi University of Dundee K-Ras...
BioCentury | Jun 27, 2019
Distillery Therapeutics

Chemically induced knockdown of SMARCA2/4 to treat AML

...DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Boehringer Ingelheim GmbH and University of Dundee showed that proteolysis-targeting...
...KG, Vienna, Austria e-mail: darryl.mcconnell@boehringer-ingelheim.com CONTACT: Alessio Ciulli, University of Dundee, Dundee, U.K. e-mail: a.ciulli@dundee.ac.uk Inhua Muijrers-Chen Boehringer Ingelheim GmbH University of Dundee SWI/SNF...
BioCentury | Jun 5, 2019
Company News

June 5 Company Quick Takes: Enzyvant's athymia candidate gets Priority review; plus Alnylam, Corbin and Institute Pasteur

...treat MS Corbin Therapeutics Inc. (Montreal, Quebec) licensed multiple small molecule USP15 inhibitors from the University of Dundee...
...Staff Writer givosiran (ALN-AS1) RVT-802 Alnylam Pharmaceuticals Inc. Corbin Therapeutics Inc. Enzyvant Sciences GmbH Institut Pasteur of Shanghai Chinese Academy of Sciences University of Dundee Ubiquitin...
BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

...falciparum lysine-tRNA ligase and Cryptosporidium lysine-tRNA ligase that could help treat malaria and Cryptosporidium infections University of Dundee...
BioCentury | Apr 22, 2019
Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

...published online April 16, 2019 doi:10.1016/j.celrep.2019.03.067 CONTACT: D. Grahame Hardie, University of Dundee, Scotland, U.K. email: d.g.hardie@dundee.ac.uk Claire Quang University of Dundee Mitochondrial...
BioCentury | Apr 10, 2019
Distillery Therapeutics

Imidazopyrimidine-based inhibitor of Leishmania proteasome identified to treat visceral leishmaniasis

...Natl. Acad. Sci. USA ; published online Apr. 8, 2019 doi:10.1073/pnas.1820175116 CONTACT: Kevin D. Read, University of Dundee...
...as above email: p.g.wyatt@dundee.ac.uk CONTACT: Maria Marco, GlaxoSmithKline plc, Tres Cantos, Spain email: maria.m.marco@gsk.com Claire Quang GlaxoSmithKline plc University of Dundee Leishmania...
BioCentury | Apr 2, 2019
Distillery Therapeutics

Microbial lysine-tRNA ligase inhibitor for malaria and Cryptosporidium

...published online Mar. 18, 2019 doi:10.1073/pnas.1814685116 CONTACT: Ian H. Gilbert, University of Dundee, Dundee, U.K. email: i.h.gilbert@dundee.ac.uk Claire Quang University of Dundee Cryptosporidium...
Items per page:
1 - 10 of 83
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...approach that does not depend on E3 ubiquitin ligases.The Glasglow-based company spun out of the University of Dundee...
...million) Investors: Advent Life Sciences, Scottish Investment Bank and BioMotivCEO: Nicola ThompsonPatents: None issued Danielle Golovin Amphista Therapeutics Ltd. University of Dundee Advent...
BioCentury | Apr 9, 2020
Finance

April 8 Quick Takes: Amphista’s series A; Invitae, Fudan-Zhangjiang and MedGenome

...investor BioMotiv. The Glasgow-based company, which spun out of Professor Alessio Ciulli’s labs at the University of Dundee...
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...was developed using Exscientia’s Centaur Chemist AI platform, which combines AI and human expertise. The University of Dundee...
...Discoidin domain receptor tyrosine kinase 1 Karen Tkach Tuzman, Associate Editor Exscientia Ltd. Dainippon Sumitomo Pharma Co. Ltd. AI DSP-1181 University of Dundee...
BioCentury | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

...Tokyo:4523) is the latest company to enter the targeted degradation field through a collaboration with University of Dundee...
...plc Jazz Pharmaceuticals plc Mirati Therapeutics Inc. Myovant Sciences GmbH Neurocrine Biosciences Inc. Novartis Novartis AG Novo Nordisk A/S Redx Pharma plc Revolution Medicines Inc. Roche Sanofi University of Dundee K-Ras...
BioCentury | Jun 27, 2019
Distillery Therapeutics

Chemically induced knockdown of SMARCA2/4 to treat AML

...DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Boehringer Ingelheim GmbH and University of Dundee showed that proteolysis-targeting...
...KG, Vienna, Austria e-mail: darryl.mcconnell@boehringer-ingelheim.com CONTACT: Alessio Ciulli, University of Dundee, Dundee, U.K. e-mail: a.ciulli@dundee.ac.uk Inhua Muijrers-Chen Boehringer Ingelheim GmbH University of Dundee SWI/SNF...
BioCentury | Jun 5, 2019
Company News

June 5 Company Quick Takes: Enzyvant's athymia candidate gets Priority review; plus Alnylam, Corbin and Institute Pasteur

...treat MS Corbin Therapeutics Inc. (Montreal, Quebec) licensed multiple small molecule USP15 inhibitors from the University of Dundee...
...Staff Writer givosiran (ALN-AS1) RVT-802 Alnylam Pharmaceuticals Inc. Corbin Therapeutics Inc. Enzyvant Sciences GmbH Institut Pasteur of Shanghai Chinese Academy of Sciences University of Dundee Ubiquitin...
BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

...falciparum lysine-tRNA ligase and Cryptosporidium lysine-tRNA ligase that could help treat malaria and Cryptosporidium infections University of Dundee...
BioCentury | Apr 22, 2019
Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

...published online April 16, 2019 doi:10.1016/j.celrep.2019.03.067 CONTACT: D. Grahame Hardie, University of Dundee, Scotland, U.K. email: d.g.hardie@dundee.ac.uk Claire Quang University of Dundee Mitochondrial...
BioCentury | Apr 10, 2019
Distillery Therapeutics

Imidazopyrimidine-based inhibitor of Leishmania proteasome identified to treat visceral leishmaniasis

...Natl. Acad. Sci. USA ; published online Apr. 8, 2019 doi:10.1073/pnas.1820175116 CONTACT: Kevin D. Read, University of Dundee...
...as above email: p.g.wyatt@dundee.ac.uk CONTACT: Maria Marco, GlaxoSmithKline plc, Tres Cantos, Spain email: maria.m.marco@gsk.com Claire Quang GlaxoSmithKline plc University of Dundee Leishmania...
BioCentury | Apr 2, 2019
Distillery Therapeutics

Microbial lysine-tRNA ligase inhibitor for malaria and Cryptosporidium

...published online Mar. 18, 2019 doi:10.1073/pnas.1814685116 CONTACT: Ian H. Gilbert, University of Dundee, Dundee, U.K. email: i.h.gilbert@dundee.ac.uk Claire Quang University of Dundee Cryptosporidium...
Items per page:
1 - 10 of 83